ABSTRACT
Background Observational studies have identified correlations between environmental and lifestyle factors and Parkinson’s disease (PD). However, the causal direction of many of these relationships remains unclear.
Objective To infer causal relationships between smoking and alcohol intake and PD.
Methods We use a two-sample Mendelian randomization (MR) experimental design to infer causal relationships between smoking (initiation, age of initiation, heaviness, and cessation) and alcohol (drinks per week) consumption as exposure variables and PD as the health outcome. We also conduct sensitivity analyses, including testing for pleiotropic effects MR-Egger and MR-PRESSO, and multivariable MR to jointly model the effects of drinking and smoking behavior on PD risk.
Results Both alcohol intake (OR = 0.69; 95% CI 0.56-0.86; p=0.001). and smoking cessation (comparing current vs. former smokers) (IVW OR = 0.39; 95% CI 0.22 to 0.69; p=0.001) were causally associated with a reduced risk of PD. In addition, our multivariable MR results provide additional assurance that the causal association between drinks per week and PD is unlikely due to confounding by smoking behavior.
Conclusion Our findings support the role of smoking as a protective factor against PD, but only when comparing current vs. former smokers. Increased alcohol intake also had a protective effect over PD risk, and the alcohol dehydrogenase 1B (ADH1B) locus is a candidate for further investigating the mechanisms underlying this association.
Competing Interest Statement
Clemens R. Scherzer has collaborated with Pfizer, Opko, Proteome Sciences, Genzyme Inc; has consulted for Genzyme; has served as Advisor to the Michael J. Fox Foundation, NIH, Department of Defense; is on the Scientific Advisory Board of the American Parkinson Disease Association; has received funding from the NIH, the U.S. Department of Defense, the Harvard NeuroDiscovery Center, the Michael J. Fox Foundation, and American Parkinson Disease Association. The authors declare no competing interests.
Funding Statement
Carmen Domínguez-Baleón was supported by a Parkinson’s Foundation-APDA Summer Student Fellowship (PF-APDA-SFW-1913) and the UNAM “Programa 2019 para Actividades Especiales de Cooperación Interinstitucional (PAECI)”. Xianjun Dong’s work was supported by grants from the American Parkinson”s Disease Association. Miguel E. Rentería’s work was supported by the Australian National Health & Medical Research Council and the Australian Research Council through a NHMRC-ARC Dementia Research Development Fellowship (GNT1002821). Clemens R. Scherzer work was supported in part by NIH grants U01NS082157, U01NS095736, U01NS100603, and the American Parkinson Disease Association.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We obtained GWAS summary statistics from the GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN) consortium (Liu et al https://conservancy.umn.edu/handle/11299/201564) and from the most recent PD GWAS from the International Parkinson’s Disease Genomics Consortium27 (IPDGC; http://pdgenetics.org/)